Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Solasia Pharma KK (9SO) AI Stock Analysis

DE:9SO

Solasia Pharma KK

(Frankfurt:9SO)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Partnered oncology business modelIts oncology and supportive-care focus, combined with licensing and collaboration economics, ties revenue opportunities to development milestones, approvals, partner commercialization and royalties. This model can extend market reach while relying on partners for commercialization in relevant territories.
Negative Factors
Persistent cash burnSustained negative operating and free cash flow means the business is not currently funding itself through operations. Continued cash consumption can increase dependence on external financing, constrain investment choices, and create dilution or funding pressure if the pattern persists.

Solasia Pharma KK (9SO) vs. iShares MSCI Germany ETF (EWG)

-50%-40%-30%-20%-10%0%10%20%30%DE:9SO-20.50%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 41.81M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-8.1
Beta (1Y)
0.88
Revenue Growth
20.47%
EPS Growth
64.97%
Country
Germany
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Solasia Pharma KK Business Overview & Revenue Model

Company Description

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil or...

Solasia Pharma KK Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9SO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4574JP:457461NeutralJPY 13.02B18.99―1.27%13.30%66.38%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4892JP:489250NeutralJPY 5.64B-6.87――364.72%18.43%
JP:4539JP:453947NeutralJPY 5.47B-44.12―3.30%0.31%-194.72%
JP:4883JP:488342NeutralJPY 3.18B-1.17―――-5.66%
JP:4582JP:458239UnderperformJPY 3.72B-0.48――-30.58%6.93%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:9SOJP:4539JP:4574JP:4582JP:4883JP:4892Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:9SO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9SOSolasia Pharma KK0.13-0.03-20.50%
JP:4539Nippon Chemiphar Co., Ltd.1515.00-100.80-6.24%
JP:4574Taiko Pharmaceutical Co., Ltd.260.00-15.00-5.45%
JP:4582Symbio Pharmaceuticals Limited44.00-71.00-61.74%
JP:4883Modalis Therapeutics Corporation28.00-47.00-62.67%
JP:4892Cyfuse Biomedical K.K.559.00-26.00-4.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.